Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Fosrenol ODT vs Chewable Tablet in Japanese Healthy Males
NCT03074058Phase 1Completed
- Sponsor
- Bayer
- Start
- Jun 2015
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lanthanum carbonate in hyperphosphatemia, sponsored by Bayer. Primary endpoint: Daily urinary phosphate excretion at 6 days. Started Jun 2015; status: completed.
02
Drugs
lanthanum carbonate
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT03074058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03074058.